MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

Trial Details

NCT ID
NCT04110301
Phase
PHASE1 / PHASE2
Sponsor
Beijing Mabworks Biotech Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Recombinant Humanized Monoclonal Antibody MIL62 Injection
  • Lenalidomide
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Adult patients, \>=18 years of age;
  • Patients with either histologically documented CD20-positive MZL or FL, WHO grade 1, 2 or 3a
  • Evidence of progression or lack of response following at least 1 prior treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →